Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $18.0 million.

  • Indivior Pharmaceuticals' Change in Receivables rose 30000.0% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 8750.0%. This contributed to the annual value of $1.0 million for FY2024, which is 9696.97% down from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Change in Receivables is $18.0 million, which was up 30000.0% from -$4.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Change in Receivables ranged from a high of $59.0 million in Q4 2023 and a low of -$18.0 million during Q3 2023
  • Over the past 4 years, Indivior Pharmaceuticals' median Change in Receivables value was -$1.0 million (recorded in 2022), while the average stood at $4.2 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first crashed by 170000.0% in 2023, then surged by 30000.0% in 2025.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Change in Receivables stood at $19.0 million in 2022, then surged by 210.53% to $59.0 million in 2023, then crashed by 93.22% to $4.0 million in 2024, then surged by 350.0% to $18.0 million in 2025.
  • Its Change in Receivables stands at $18.0 million for Q3 2025, versus -$4.0 million for Q2 2025 and -$11.0 million for Q1 2025.